Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Posted by Geri Gentry on Oct 14th, 2026

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Tandem Diabetes Care stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.
Purchased $1,001 – $15,000 in shares of Alkermes (NASDAQ:ALKS) on 9/29/2026.

Tandem Diabetes Care Price Performance

Shares of TNDM stock opened at $16.65 on Wednesday. The company has a debt-to-equity ratio of 4.62, a current ratio of 3.18 and a quick ratio of 2.65. The company has a market capitalization of $1.16 billion, a PE ratio of -17.90 and a beta of 1.66. The firm’s 50-day moving average is $19.20 and its two-hundred day moving average is $18.01. Tandem Diabetes Care, Inc. has a 12 month low of $12.26 and a 12 month high of $29.65.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical device company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.01. The firm had revenue of $254.56 million for the quarter, compared to analyst estimates of $254.99 million. Tandem Diabetes Care had a negative net margin of 6.08% and a negative return on equity of 45.97%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.78) EPS. Analysts predict that Tandem Diabetes Care, Inc. will post -0.66 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on TNDM shares. Truist Financial cut their price objective on Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, September 24th. Deutsche Bank Aktiengesellschaft started coverage on shares of Tandem Diabetes Care in a research report on Tuesday, June 23rd. They issued a “hold” rating and a $15.50 target price on the stock. Oppenheimer reaffirmed an “outperform” rating on shares of Tandem Diabetes Care in a research note on Friday, August 7th. Barclays raised shares of Tandem Diabetes Care to a “hold” rating in a research note on Wednesday, October 7th. Finally, Citigroup dropped their price target on shares of Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, September 30th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $27.08.

Get Our Latest Research Report on TNDM

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Leonteq Securities AG increased its holdings in Tandem Diabetes Care by 21.7% in the 1st quarter. Leonteq Securities AG now owns 9,501 shares of the medical device company’s stock valued at $182,000 after purchasing an additional 1,695 shares in the last quarter. Diversified Trust Co lifted its stake in shares of Tandem Diabetes Care by 9.1% during the first quarter. Diversified Trust Co now owns 21,332 shares of the medical device company’s stock worth $409,000 after purchasing an additional 1,774 shares in the last quarter. OP Asset Management Ltd purchased a new stake in shares of Tandem Diabetes Care in the first quarter worth about $35,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Tandem Diabetes Care in the second quarter valued at about $33,000. Finally, 180 Wealth Advisors LLC grew its stake in shares of Tandem Diabetes Care by 17.3% in the first quarter. 180 Wealth Advisors LLC now owns 15,763 shares of the medical device company’s stock valued at $302,000 after buying an additional 2,320 shares in the last quarter.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Tandem Diabetes Care Company Profile

(Get Free Report)

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to work with continuous glucose monitoring (CGM) systems and digital health tools to help automate and personalize insulin therapy.

Tandem’s product portfolio includes the t:slim X2 insulin pump, which features a rechargeable design and software that supports automated insulin delivery. The company also offers the t:slim X2 pump with Control-IQ technology, an algorithm designed to adjust insulin delivery based on CGM readings, and the compact Tandem Mobi pump.